Halozyme Therapeutics Inc. Stock
Halozyme Therapeutics Inc. gained 0.280% compared to yesterday.
We see a rather positive sentiment for Halozyme Therapeutics Inc. with 20 Buy predictions and 2 Sell predictions.
As a result the target price of 70 € shows a positive potential of 20.27% compared to the current price of 58.2 € for Halozyme Therapeutics Inc..
For the coming years our community has positive and negative things to say abot the Halozyme Therapeutics Inc. stock. Criterium "Worthwhile Investment for the next years" gathered the most positive votes but regarding "Expected dividend yield" there were negative voices in the community.
Pros and Cons of Halozyme Therapeutics Inc. in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
?
S********** s********
Cons
?
G***** c******* t* c**********
?
B****
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Halozyme Therapeutics Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Halozyme Therapeutics Inc. | 0.280% | -1.057% | -12.827% | 5.183% | -0.956% | 33.073% | 69.114% |
| United Therapeutics | -0.290% | -2.132% | 2.805% | 45.019% | -2.223% | 78.700% | 211.791% |
| Iovance Biotherapeutics Inc. | 12.440% | 23.134% | 97.260% | 5.656% | 66.948% | -42.181% | -85.409% |
| Ligand Pharmaceuticals | 2.270% | 12.500% | 7.143% | 66.667% | 8.434% | 154.309% | 48.270% |
Comments
Halozyme Therapeutics (NASDAQ:HALO) had its price target raised by analysts at Benchmark Co. from $75.00 to $90.00. They now have a "buy" rating on the stock.
Show more
Ratings data for HALO provided by MarketBeat
Halozyme Therapeutics (NASDAQ:HALO) had its "buy" rating reaffirmed by analysts at TD Cowen.
Show more
Ratings data for HALO provided by MarketBeat
Halozyme Therapeutics (NASDAQ:HALO) had its "buy" rating reaffirmed by analysts at Benchmark Co..
Show more
Ratings data for HALO provided by MarketBeat
News
2 Under-the-Radar Biotech Stocks Set to Boom in 2026
The biotech sector returned to health in 2025 after years of sickly returns. A key sign of vitality was the SPDR S&P Biotech ETF (NASDAQ: IBB), which rose 27% in 2025, nearly doubling the 16% gain
Halozyme Therapeutics: A 6.3 Rating and a Future Full of Uncertainty
Explore the exciting world of Halozyme Therapeutics (NASDAQ: HALO) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights
The Healthcare Sector Is Surging. Here's 1 Stock Every Investor Should Have on Their Radar.
Over the last three months, the S&P 500 healthcare sector has risen 13%, compared to the broader S&P 500 index's 7% increase.
However, one stock that hasn't matched its sector's returns is Halozyme